Join our community of smart investors

Hutchison China Meditech's drug trial fails

The drug developer has seen one of its cancer trials fail at the final hurdle
November 21, 2018

A final-phase trial of Hutchison China Meditech’s (HCM) cancer drug fruquintinib has failed to demonstrate “a statistically significant increase in overall survival” amongst advanced non-small-cell lung cancer patients in China.

IC TIP: Buy at 4,880p
This is subscriber only content
Start your trial to keep reading
PRINT AND DIGITAL trial

Get 12 weeks for £12
  • Essential access to the website and app
  • Magazine delivered every week
  • Investment ideas, tools and analysis
Have an account? Sign in